Shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) traded down 1.3% during mid-day trading on Tuesday . The stock traded as low as $44.15 and last traded at $44.49, with a volume of 184,733 shares trading hands. The stock had previously closed at $45.06.

Several analysts have issued reports on the stock. Oppenheimer Holdings Inc. restated a “buy” rating on shares of Five Prime Therapeutics in a research report on Monday, April 18th. Zacks Investment Research lowered shares of Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, April 20th. BMO Capital Markets assumed coverage on shares of Five Prime Therapeutics in a research report on Tuesday, April 12th. They set a “market perform” rating and a $50.00 price target for the company. Credit Suisse Group AG reiterated a “buy” rating on shares of Five Prime Therapeutics in a report on Wednesday, June 8th. Finally, Jefferies Group reiterated a “buy” rating on shares of Five Prime Therapeutics in a report on Sunday, May 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $45.80.

The company has a market capitalization of $1.17 billion and a price-to-earnings ratio of 4.91. The company has a 50 day moving average of $42.49 and a 200 day moving average of $39.33.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Thursday, May 5th. The company reported ($0.49) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.22. The business earned $6.50 million during the quarter, compared to the consensus estimate of $5.26 million. During the same period in the prior year, the firm earned ($0.44) earnings per share. The business’s quarterly revenue was up 51.2% on a year-over-year basis. Equities research analysts anticipate that Five Prime Therapeutics Inc. will post ($2.35) EPS for the current fiscal year.

In other news, CFO Marc Belsky sold 34,102 shares of the business’s stock in a transaction that occurred on Friday, April 22nd. The stock was sold at an average price of $50.00, for a total transaction of $1,705,100.00. Following the sale, the chief financial officer now directly owns 88,410 shares in the company, valued at $4,420,500. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Lewis T. Williams sold 48,671 shares of the business’s stock in a transaction that occurred on Thursday, April 21st. The shares were sold at an average price of $48.05, for a total value of $2,338,641.55. Following the sale, the chief executive officer now owns 341,078 shares in the company, valued at $16,388,797.90. The disclosure for this sale can be found here.

Several hedge funds have recently added to or reduced their stakes in FPRX. ProShare Advisors LLC boosted its stake in Five Prime Therapeutics by 16.9% in the fourth quarter. ProShare Advisors LLC now owns 25,418 shares of the company’s stock worth $1,055,000 after buying an additional 3,682 shares in the last quarter. Oxford Asset Management purchased a new stake in Five Prime Therapeutics during the fourth quarter worth about $1,241,000. Russell Frank Co purchased a new stake in Five Prime Therapeutics during the fourth quarter worth about $1,265,000. EAM Investors LLC purchased a new stake in Five Prime Therapeutics during the fourth quarter worth about $1,549,000. Finally, California State Teachers Retirement System boosted its stake in Five Prime Therapeutics by 7.3% in the fourth quarter. California State Teachers Retirement System now owns 42,025 shares of the company’s stock worth $1,744,000 after buying an additional 2,842 shares in the last quarter.

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.